Metabolic Dysfunction in Alzheimer’s Disease: Brain Glucose Hypometabolism as an Early Precursor to Amyloid and Tau Pathology
Journal of Clinical Medicine · 01.03.2026 · 15 (5) · 1884
DOI: 10.3390/jcm15051884 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.03.2026. Verfasst von Rafail C Christodoulou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuroimaging and Neurointervention, Department of Radiology, Stanford University, Stanford, CA 94304, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Objective
Alzheimer’s disease (AD) is traditionally characterized by amyloid-β and tau pathology; however, accumulating evidence indicates that metabolic and inflammatory dysfunctions are early, central contributors to disease development. This narrative review explores how metabolic disturbances influence AD pathophysiology.
Methods
A comprehensive literature search was performed on PubMed, Embase, and Scopus. Selected studies were original studies or reviews published in English within the past five years involving human subjects. Case reports, case series, editorials, and non-human studies were excluded. A total of 64 articles were reviewed and summarized.
Results
Cerebral glucose hypometabolism, mitochondrial impairment, insulin resistance, oxidative stress, and neuroinflammation were observed throughout the AD spectrum. These metabolic changes often appeared before significant amyloid accumulation and were more closely linked to tau pathology and cognitive decline. Early microglial activation was linked to transient glucose hypermetabolism, progressing to glucose hypometabolism and neurodegeneration as the disease advanced.
Conclusions
AD is associated with a gradual breakdown of metabolic and inflammatory homeostasis, which occurs before and promotes the development of traditional neuropathological features. Addressing early metabolic vulnerabilities may be essential for effective disease intervention and prevention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neuroimaging and Neurointervention, Department of Radiology, Stanford University, Stanford, CA 94304, USA.
- Department of Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 1st Department of Neurology, Medical School, National and Kapodistrian University of Athens, Eginition Hospital, 15772 Athens, Greece.
- Department of Biological Sciences, Kean University, Union, NJ 07083, USA.
ORCID-Profile: Rafail C Christodoulou, Daniel Eller, Platon S Papageorgiou, Efthalia Angelopoulou, Sokratis G Papageorgiou
Zitieren
APA
Christodoulou, R. C., Eller, D., Papageorgiou, P. S., Angelopoulou, E., Vassiliou, E., & Papageorgiou, S. G. (2026). Metabolic Dysfunction in Alzheimer’s Disease: Brain Glucose Hypometabolism as an Early Precursor to Amyloid and Tau Pathology. Journal of Clinical Medicine, 15(5), 1884. https://doi.org/10.3390/jcm15051884
Vancouver
Christodoulou RC, Eller D, Papageorgiou PS, Angelopoulou E, Vassiliou E, Papageorgiou SG. Metabolic Dysfunction in Alzheimer’s Disease: Brain Glucose Hypometabolism as an Early Precursor to Amyloid and Tau Pathology. Journal of Clinical Medicine. 2026;15(5):1884. doi:10.3390/jcm15051884
BibTeX
@article{Christodoulou2026,
author = {Christodoulou, Rafail C and Eller, Daniel and Papageorgiou, Platon S and Angelopoulou, Efthalia and Vassiliou, Evros and Papageorgiou, Sokratis G},
title = {Metabolic Dysfunction in Alzheimer’s Disease: Brain Glucose Hypometabolism as an Early Precursor to Amyloid and Tau Pathology},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {5},
pages = {1884},
doi = {10.3390/jcm15051884}
}
EUVIMED